Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLCComparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC, Published online: 04 February 2019; doi:10.1038/s41571-019-0173-9The advent of effective molecularly targeted treatments and immunotherapies for non-small-cell lung cancer (NSCLC) has greatly improved patient outcomes. Whereas most patients selected for treatment with molecularly targeted drugs derive benefits from these agents, benefit from immunotherapy is more difficult to predict. Herein, Camidge and colleagues compare and contrast predictive biomarkers for immunotherapy and targeted therapy of NSCLC to highlight considerations for biomarker development.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research